GR20000100264A - ΝΕΑ ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΟΥ ΥΔΡΟΧΛΩΡΙΚΟΥ 6-ΥΔΡΟΞΥ-3-(4-[2-(ΠΙΠΕΡΙΔΙΝ-1-ΥΛ)ΑΙΘΟΞΥ]ΦΑΙΝΟΞΥ-2-(4-ΜΕΘΟΞΥΦΑΙΝΥΛ)-ΒΕΝΖΟ[b]-ΘΕΙΟΦΑΙΝΙΟΥ - Google Patents
ΝΕΑ ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΟΥ ΥΔΡΟΧΛΩΡΙΚΟΥ 6-ΥΔΡΟΞΥ-3-(4-[2-(ΠΙΠΕΡΙΔΙΝ-1-ΥΛ)ΑΙΘΟΞΥ]ΦΑΙΝΟΞΥ-2-(4-ΜΕΘΟΞΥΦΑΙΝΥΛ)-ΒΕΝΖΟ[b]-ΘΕΙΟΦΑΙΝΙΟΥInfo
- Publication number
- GR20000100264A GR20000100264A GR20000100264A GR2000100264A GR20000100264A GR 20000100264 A GR20000100264 A GR 20000100264A GR 20000100264 A GR20000100264 A GR 20000100264A GR 2000100264 A GR2000100264 A GR 2000100264A GR 20000100264 A GR20000100264 A GR 20000100264A
- Authority
- GR
- Greece
- Prior art keywords
- piperidin
- benzo
- methoxyphenyl
- phenoxy
- ethoxy
- Prior art date
Links
- NHSNLUIMAQQXGR-UHFFFAOYSA-N hydron;2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol;chloride Chemical compound Cl.C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 NHSNLUIMAQQXGR-UHFFFAOYSA-N 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 229940011871 estrogen Drugs 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Developmental Biology & Embryology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μία νέα ένυδρη κρυσταλλική μορφή του υδροχλωρικού 6-υδροξυ-3-(4-[2-(πιπεριδιν-1-υλ)αιθοξυ]φαινοξυ)-2-(4-μεθοξυφαινυλ)βενζο[b]θειοφαινίου και σε χρήσεις της, περιλαμβανομένης της αναστολής νοσηρών καταστάσεων σχετιζομένων με την έλλειψη οιστρογόνων οι οποίες περιλαμβάνουν τις καρδιοαγγειακές νόσους, την υπερλιπιδαιμία και την οστεοπόρωση, και της αναστολής άλλων παθολογικών καταστάσεων όπως η ενδομητρίωση, η ίνωση της μήτρας, ο εξαρτώμενος από οιστρογόνα καρκίνος (περιλαμβανομένου του καρκίνου του μαστού και της μήτρας), ο καρκίνος του προστάτη, η καλοήθης υπερπλασία του προστάτη, οι διαταραχές του ΚΝΣ περιλαμβανομένης της νόσου του Alzeimer, της προλήψεως του καρκίνου του μαστού και της αυξητικής ρυθμίσεως της ChAT.ΰ
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14618499P | 1999-07-29 | 1999-07-29 | |
US14764299P | 1999-08-06 | 1999-08-06 | |
US14982099P | 1999-08-19 | 1999-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
GR20000100264A true GR20000100264A (el) | 2001-03-30 |
Family
ID=27386367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20000100264A GR20000100264A (el) | 1999-07-29 | 2000-07-28 | ΝΕΑ ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΟΥ ΥΔΡΟΧΛΩΡΙΚΟΥ 6-ΥΔΡΟΞΥ-3-(4-[2-(ΠΙΠΕΡΙΔΙΝ-1-ΥΛ)ΑΙΘΟΞΥ]ΦΑΙΝΟΞΥ-2-(4-ΜΕΘΟΞΥΦΑΙΝΥΛ)-ΒΕΝΖΟ[b]-ΘΕΙΟΦΑΙΝΙΟΥ |
Country Status (45)
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085147A2 (en) * | 2000-05-08 | 2001-11-15 | Eli Lilly And Company | STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF |
EP1757291A3 (en) * | 2000-05-08 | 2009-07-15 | Eli Lilly & Company | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
US7122203B2 (en) | 2000-05-08 | 2006-10-17 | Eli Lilly And Company | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof |
AU2005200809B2 (en) * | 2000-05-08 | 2006-05-11 | Eli Lilly And Company | Stabilized Formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) Ethoxy]phenoxy)-2-(4-methoxyphenyl) Benzo[b]thiophene and Salts Thereof |
KR20030037690A (ko) * | 2000-10-20 | 2003-05-14 | 일라이 릴리 앤드 캄파니 | 6-히드록시-3-(4-[2-(피페리딘-1-일)에톡시]페녹시)-2-(4-메톡시페닐)벤조[b]티오펜 히드로클로라이드의 신규 결정형 |
US6921827B2 (en) | 2000-11-27 | 2005-07-26 | Eli Lilly And Company | Process for preparing 3-aryl-benzo{b} thiophenes |
ES2349798T3 (es) * | 2004-07-22 | 2011-01-11 | Eli Lilly And Company | Hidrato variable cristalino de la sal hemisuccinato de (s)-6-(4-(2-((3-(9h-carbazol-4-iloxi)-2-hidroxipropil)amino)-2-metilpropil)fenoxi)-3-piridinocarboxamida. |
CA2590997A1 (en) * | 2004-12-23 | 2006-07-06 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer`s disease |
WO2006088648A1 (en) * | 2005-02-11 | 2006-08-24 | Eli Lilly And Company | Compositions and methods for treating dyslipidemia |
DE102008057230A1 (de) * | 2008-11-11 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin |
CN113325183B (zh) * | 2021-06-01 | 2022-11-15 | 中国医学科学院北京协和医院 | 一种用于鉴别诊断em/fem的试剂盒 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0729956A1 (en) * | 1995-02-28 | 1996-09-04 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
WO1998045287A1 (en) * | 1997-04-09 | 1998-10-15 | Eli Lilly And Company | Treatment of central nervous system disorders with selective estrogen receptor modulators |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
EP1204656A2 (en) * | 1999-07-29 | 2002-05-15 | Eli Lilly And Company | A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride |
-
2000
- 2000-07-17 DE DE60005693T patent/DE60005693T2/de not_active Expired - Fee Related
- 2000-07-17 WO PCT/US2000/016332 patent/WO2001009115A2/en active IP Right Grant
- 2000-07-17 AT AT00950222T patent/ATE251151T1/de not_active IP Right Cessation
- 2000-07-17 AU AU63355/00A patent/AU6335500A/en not_active Abandoned
- 2000-07-17 EP EP00950222A patent/EP1204655B1/en not_active Expired - Lifetime
- 2000-07-17 ES ES00950222T patent/ES2208384T3/es not_active Expired - Lifetime
- 2000-07-18 LV LVP-00-95A patent/LV12733B/lv unknown
- 2000-07-24 CZ CZ20002717A patent/CZ300356B6/cs not_active IP Right Cessation
- 2000-07-24 ID IDP20000630A patent/ID26679A/id unknown
- 2000-07-25 HR HR20000502A patent/HRP20000502B1/xx not_active IP Right Cessation
- 2000-07-26 EG EG20000954A patent/EG24196A/xx active
- 2000-07-27 CO CO00056522A patent/CO5180572A1/es not_active Application Discontinuation
- 2000-07-27 IL IL137552A patent/IL137552A/en not_active IP Right Cessation
- 2000-07-27 NL NL1015822A patent/NL1015822C2/nl not_active IP Right Cessation
- 2000-07-27 TR TR2000/02205A patent/TR200002205A2/xx unknown
- 2000-07-28 PL PL00341748A patent/PL341748A1/xx not_active Application Discontinuation
- 2000-07-28 HU HU0003005A patent/HUP0003005A2/hu unknown
- 2000-07-28 MD MDA20000161A patent/MD2335G2/ro not_active IP Right Cessation
- 2000-07-28 JP JP2000228949A patent/JP2001048880A/ja active Pending
- 2000-07-28 AU AU48911/00A patent/AU779559B2/en not_active Ceased
- 2000-07-28 AR ARP000103929A patent/AR029176A1/es not_active Application Discontinuation
- 2000-07-28 BR BR0003211-5A patent/BR0003211A/pt not_active Application Discontinuation
- 2000-07-28 LU LU90616A patent/LU90616B1/fr active
- 2000-07-28 PT PT102501A patent/PT102501A/pt not_active IP Right Cessation
- 2000-07-28 SV SV2000000134A patent/SV2002000134A/es unknown
- 2000-07-28 NZ NZ506045A patent/NZ506045A/en unknown
- 2000-07-28 CN CNB001222406A patent/CN1138771C/zh not_active Expired - Fee Related
- 2000-07-28 LT LT2000075A patent/LT4789B/lt not_active IP Right Cessation
- 2000-07-28 MY MYPI20003448A patent/MY120393A/en unknown
- 2000-07-28 MX MXPA00007462A patent/MXPA00007462A/es active IP Right Grant
- 2000-07-28 SE SE0002793A patent/SE0002793L/xx unknown
- 2000-07-28 IT IT2000MI001758A patent/IT1318659B1/it active
- 2000-07-28 KR KR1020000043586A patent/KR100733094B1/ko not_active IP Right Cessation
- 2000-07-28 BE BE2000/0477A patent/BE1013410A3/fr not_active IP Right Cessation
- 2000-07-28 GR GR20000100264A patent/GR20000100264A/el not_active IP Right Cessation
- 2000-07-28 AT AT0132300A patent/AT502317A1/de not_active Application Discontinuation
- 2000-07-28 SG SG200004287A patent/SG90737A1/en unknown
- 2000-07-28 CA CA002314685A patent/CA2314685C/en not_active Expired - Fee Related
- 2000-07-28 FI FI20001721A patent/FI20001721A/fi not_active Application Discontinuation
- 2000-07-28 DE DE10036855A patent/DE10036855A1/de not_active Withdrawn
- 2000-07-28 TW TW089115152A patent/TWI271403B/zh not_active IP Right Cessation
- 2000-07-28 FR FR0009972A patent/FR2798384B1/fr not_active Expired - Fee Related
- 2000-07-28 GB GB0018636A patent/GB2352716A/en not_active Withdrawn
- 2000-07-28 NO NO20003876A patent/NO325594B1/no not_active IP Right Cessation
- 2000-07-28 DK DK200001150A patent/DK176771B1/da not_active IP Right Cessation
- 2000-07-28 SI SI200000173A patent/SI20427B/sl not_active IP Right Cessation
- 2000-07-31 PE PE2000000758A patent/PE20010383A1/es not_active Application Discontinuation
-
2001
- 2001-08-08 HK HK01105511A patent/HK1034962A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0729956A1 (en) * | 1995-02-28 | 1996-09-04 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
WO1998045287A1 (en) * | 1997-04-09 | 1998-10-15 | Eli Lilly And Company | Treatment of central nervous system disorders with selective estrogen receptor modulators |
Non-Patent Citations (1)
Title |
---|
RABASSEDA, X. ET AL: "Arzoxifene hydrochloride", DRUGS FUTURE (1999), 24(6), 599-604, XP002159973 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR20000100264A (el) | ΝΕΑ ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΟΥ ΥΔΡΟΧΛΩΡΙΚΟΥ 6-ΥΔΡΟΞΥ-3-(4-[2-(ΠΙΠΕΡΙΔΙΝ-1-ΥΛ)ΑΙΘΟΞΥ]ΦΑΙΝΟΞΥ-2-(4-ΜΕΘΟΞΥΦΑΙΝΥΛ)-ΒΕΝΖΟ[b]-ΘΕΙΟΦΑΙΝΙΟΥ | |
MY128764A (en) | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL) BENZO [b] THIOPHENE HYDROCHLORIDE | |
JO2239B1 (en) | Method for preparing benzothophen derivatives | |
WO2002034741A3 (en) | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE | |
DE69825381D1 (de) | Benzothiophene | |
RU2000120574A (ru) | НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА | |
TH55348B (th) | รูปผลึกแบบใหม่ของ 6-ไฮดรอกซี-3-(4-[2-พิเพอริดิน-1-อิล) เอทอกซี] ฟีนอกซี)-2-(4-เมทอกซีเฟนิล)เบนโซ[3] ไทโอฟีนไฮโดรดคลอไรด์ | |
HU0102118D0 (en) | Process for chloromethylation | |
RU2000120575A (ru) | НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА | |
AU5531001A (en) | Stabilized formulations of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy)phenoxy)-2-(4-methoxyphenyl) benzo(B)thiophene and salts thereof | |
ZA200003838B (en) | A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride. | |
ZA200003837B (en) | A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride. | |
TJ20000620A (en) | A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl) ethoxy Ü phenoxy) - 2 - (4-methanoxyphenyl) benzo ÄbÜ thiophene hidrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ML | Lapse due to non-payment of fees |
Effective date: 20110202 |